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Enforcing Federal Drug Laws in StatesWhere
Medical Marijuana Is Lawful
On January 4, 2018,Attorney General Jeff Sessions is-
suedamemorandumimmediately rescindingtheObama
Administration’s long-standing guidance limiting fed-
eral enforcementofmedicalmarijuana.1 Federal lawcre-
atesharshpenalties for thecultivation,distribution, and
possessionofmarijuana,whichSessionsdeemeda“dan-
gerous drug” and a “serious crime.” The memorandum
placesphysicians andpatients at riskof arrest andpros-
ecution in 29 states and the District of Columbia that
have legalized medical use of marijuana (eTable in the
Supplement).
This Department of Justice (DOJ) guidance came
at a time of increasing acceptance, accessibility, and use
of cannabis and its derivatives. According to a 2015
nationwide survey, an estimated 22.2 million individu-
als in the United States aged 12 years or older reported
cannabis use in the past 30 days; 90% said their pri-
mary use was recreational, with 10% solely for medical
purposes; 36% reported mixed medical and recre-
ational use.2 A 2017 national poll found that 61% of
respondents support legalization of marijuana and 71%
oppose federal enforcement.3 In 2016, an estimated
1.2 million adults accessedmedicinal marijuana through
state-licensed dispensaries or home cultivation.4
The Case for Research
Marijuana is classified as a Schedule I drug (like heroin)
under theControlledSubstancesAct (CSA)of 1970,with
high potential for abuse and no recognized or ap-
provedmedical uses. Theaggregatedevidenceofmari-
juana’s medical benefits, harms, and potential role as a
gateway tomore serious drug dependency is uncertain
and incomplete.
The National Academies found evidence that pa-
tients treated with cannabis or cannabinoids experi-
enced significant pain relief. Short-termuseof oral can-
nabinoids improved reported symptoms of multiple
sclerosis–relatedmuscle spasms.Oral cannabinoids can
prevent or ameliorate chemotherapy-induced nausea
and vomiting.5 However, evidence of effectiveness is
lacking for diverse conditions forwhich cannabis is pre-
scribed, includingcancers,glaucoma, irritablebowelsyn-
drome,epilepsy,anddystonia.For theseconditions,pre-
scribing physicians often rely on limited clinical and
anecdotal evidence.6
Like many controlled substances, marijuana has
significant adverse effects. It can induce dizziness,
panic attacks, nausea, vomiting, hallucinations, and
temporary learning and memory impairments. Regu-
lar use increases risks of substance dependency
and smoking-induced respiratory symptoms. It
also increases injury risks, including through vehicular
collisions.
Certain groups couldbe at increased risk, including
children, adolescents, and pregnant women. Habitual
marijuana smoking at a young age can limit educational
and employment opportunities. Newborns of women
who smoke during pregnancy may have low birth
weights or develop longer-term cognitive impair-
ments. Ingestionofmarijuana-infused “edibles” by chil-
drenhas led to life-threateningpoisonings.After imple-
mentation of legal recreational use in Colorado in 2014,
therewas a34% increase in hospitalizations of children
related tomarijuana.7
Despite the imperative for better evidence, mari-
juana’s Schedule I status and absence of US Food and
Drug Administration approval pose major research bar-
riers. Research funding is limited. High-
quality cannabis for research is scarce.
No standards have been set for the
purity and potency of marijuana, result-
ing in varied quality and dosage. The
amount of Δ9-tetrahydrocannabinol
(THC), the principal psychoactive com-
ponent, ranges extensively. Contami-
nants in marijuana, including fungi or pesticides, can
be toxic.
Law, Policy, and Politics
BeginningwithCalifornia’sCompassionateUseActin1996,
stateshavereducedpunitivesanctions formarijuanause.
Nearly all states allow somemedicinal uses of THC (clas-
sifiedseparatelyundertheCSA).Statesauthorizingmedi-
calmarijuanadelineateconditions forwhich itcanbepre-
scribed.California’sphysicianscanprescribemarijuanafor
any“chronicorpersistentmedicalsymptom”thatlimitspa-
tients’ daily life activities or seriously impairs physical or
mental health. Several states limit access through an au-
thorized dispensary, while others (eg, Colorado) permit
home cultivation (eTable in the Supplement).
Legalchallengestostatemarijuana lawshaveproved
largelyunsuccessful, includinggroupsseekingtowithdraw
medicalmarijuanafromballotreferendumsortowieldzon-
ingandland-use lawstoconstraincultivationofmarijuana
andplacementofdispensaries.Workplace“zerotolerance”
policies also pose employment risks formarijuana users.
In Gonzales v Raich,8 the Supreme Court held that
the DOJ can enforce federal drug laws even for purely
On an issue as consequential as
marijuana, the nation needs consistent
legal norms based on the best available
scientific evidence.
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intrastate manufacture and possession of medical marijuana. The
CSA preemption applies only if federal and state laws “cannot con-
sistently stand together.”5State legalizationofmedicalmarijuanaar-
guably can coexist with federal law, but the DOJ’s new guidance
places physicians at risk of liability to which courts may defer.
TheDOJoverturned theObamaAdministration’s guidance cen-
teredonprosecutionoflarge-scalemarijuanaproductionfacilities9with
goalsofpreventingminors’accesstomarijuana, illegalsales,coverttraf-
ficking, and intoxicateddriving. Since2016,Congresshas supported
statesovereignty,enactingtheRohrabacher-BlumenauerAmendment,
whichprohibits useof federal funding to impede statemedicalmari-
juanalaws.SessionsaskedCongresstoremovetheriderfromthe2018
spending bill despite bipartisan support.
Theneteffectof theDOJ’s2018memorandumisunclear.Physi-
ciansprescribingandpatientsusingcannabis lawfullyunderstatestat-
utescouldbesubjecttofederalprosecution.Still,prosecutorshavewide
discretionand limited resources.Manywill notbring charges against
individualswhorelyonstate law.SeveralUSattorneyshavealreadyan-
nounced their intention to followObama-eraguidance. State legisla-
torsandpolicymakers inmedicalmarijuana jurisdictionshavepledged
to use all legal andpoliticalmeans to defend states’ rights.
Toward Rational Medical Marijuana Policies
Althoughpublicopinionandstateactionhavetrendedstronglytoward
permittinguseofmarijuana,especially formedicalpurposes, contro-
versy continues toexist. Thespecterof federal prosecutioncould re-
frainphysicians,patients, anddispensaries fromprovidingmarijuana
instateswherethedrug is lawfulanddissuadeadditional jurisdictions
fromlegalizingmarijuana.Publicpolicyformedandimplementedinthe
contextof inconsistent federalandstate laws,unpredictable legalen-
forcement,and insufficientscientificevidence isunsustainable.Ratio-
nal policies should followa 3-pronged agenda.
A Solid Research Foundation
Soundpolicy requiresastrongevidencebase.Scientific studiescould
quellongoingdisagreementsaboutmarijuana’smedicaleffectiveness,
harms, and status as a gatewaydrug. Yet limited funding and restric-
tive access touniformly high-quality cannabis have sharply curtailed
longitudinal studiesonadrugalready inwideuse. Physicians require
rigorousevidencetoinformprescribingpracticesandcounselingofpa-
tients.Atpresent,wideregionalvariations inprescribingpracticesex-
ist,andpatientsdonothaveaccesstoconsistentlyhigh-quality,uncon-
taminated cannabis—where the purity, potency, and dosage can be
ensured.Healthofficials,moreover, rarelyconductcarefulsurveillance
ofmarijuana use incidence, prevalence, andoutcomes. Public policy
on apotentially hazardouspsychotropic drug is difficultwhen short-
and long-termeffects acrosspopulationsareunderreported, insuffi-
ciently studied, andpoorly funded.
AHarmonized Legal Environment
Substantial variability of legal approaches to marijuana use exists
across jurisdictions and between states and the federal govern-
ment. Individuals in certain jurisdictions can lawfully access mari-
juana for medical use, recreational use, or both, whereas individu-
als in other jurisdictions cannot do so.
Conditions under which physicians can prescribe (or patients
canaccess)marijuana fluctuate extensively. Federal law is inconsis-
tent with policy in virtually all states. The CSA should be revised to
operateharmoniouslywithprevailingstate law.Model legislation for
medical use of marijuana, based on scientific evidence, could help
reconcile activities across jurisdictions.
Federal Law Enforcement Respectful of States’ Sovereignty
Under US constitutional design, states and localities are laborato-
ries for innovation, with state sovereignty and local home rule
respected and preserved. This requires federal prosecutorial dis-
cretion to hew to the legal environment of states that have legal-
ized marijuana use. Respecting marijuana laws is essential in
states where cannabis is prescribed and used for medical pur-
poses. On an issue as consequential as marijuana, the nation
needs consistent legal norms based on the best available scien-
tific evidence.
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